Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024
Video
10 Minutes of Antitrust: Tech Legislation, Litigation, and Risk Mitigation
Alert
Where Things Stand on Drug Pricing at the Halfway Point of 2023
Alert
Five Drug Pricing Issues to Watch in 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes
Article
Is It Game Over for PlayStation Store Antitrust Suit?
Alert
Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate
Alert
Drug Pricing Issues to Watch in 2022
Article
United States: Pharmaceutical Antitrust 2022
Alert
States Remain the Drivers of New Drug Pricing Legislation As Washington Weighs In
Alert
House Republicans Introduce Bill to Renew 2015 Trade Promotion Authority Law and Establish New Negotiating Objectives for Pharmaceuticals
Article
Third Circuit: Pharmaceutical Cases
Alert
Technology Industry Should Watch Closely as the Executive Branch and Lawmakers Set Their Sights on Antitrust
Alert
Analysis: FTC Encouraged to Ban or Limit Non-Compete Agreements in July 9, 2021 Executive Order; Breaks With Tradition, And Follows Trend of Heightened Antitrust Focus on Labor Markets
Alert
What Does President Biden’s July 9, 2021 Executive Order on Competition Mean for the Pharma Industry?
Insight
Sweeping US Order on “Promoting Competition”
The new Executive Order includes 72 initiatives instructing more than a dozen federal agencies to consider adopting rules intended to enhance competition.
Insight
What’s next for drug pricing in the US?
New challenges may lie ahead for the pharmaceutical industry
Alert
Federal Lawmakers Turn Their Sights to Drug Pricing, Introducing a Package of Bills Seeking Changes to Antitrust and Patent Law
Insight
US antitrust spotlight on the technology industry
Is 2021 a year of change?
Alert
President Biden Signs Legislation Boosting Generic and Biosimilar Drugs
Alert
Supreme Court Green Lights Arkansas Law Regulating PBM Pricing Practices
Alert
Trump Administration’s Eleventh-Hour Drug Pricing Regulations Face an Uncertain Path Forward
Article
United States: Pharmaceutical Antitrust 2021
Alert
President Trump's Most Favored Nation Policy for Medicare Drug Costs Unlikely to Bring Near Term Changes
Article
Most Courts Follow 1st Circ. Generic-Delay Ruling's Standard
Alert
Uncertainty on Drug Pricing Remains Following Trump Administration Executive Orders
Article
Why A Surge In Drug Pricing Litigation Is Unlikely
